Back

The impact of ticagrelor therapy on CABG-related bleeding in patients with STEMI managed with pPCI

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: Risk stratification and management of acute coronary syndromes Revascularisation ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Gunduz Incesu

Istanbul University-Cerrahpasa Institute of Cardiology, Istanbul (Turkiye)

6 More presentations in this session

Presentation thumbnail
GDF-15 adds to GRACE 2.0 for long-term risk prediction in ACS but echocardiographic parameters do not: A SWEDEHEART prognostication study
Doctor J. Lenell (Uppsala, SE)
Abstract Slides Video
Presentation thumbnail
Clinical efficacy of permanent internal mammary artery occlusion in chronic coronary artery disease: a double-blind, randomized, sham-controlled trial
Doctor M. Bigler (Bern, CH)
Abstract Slides Video
Presentation thumbnail
Clinical characteristics of first myocardial infarction in women by history of adverse pregnancy outcomes
Doctor M. Pehrson (Malmo, SE)
Abstract Slides Video
Presentation thumbnail
Adjunct remote ischemic conditioning to PCI in ST-segment elevation myocardial infraction patients: Systematic review and meta-analysis
Miss M. Desouki (Minneapolis, US)
Abstract Slides Video
Presentation thumbnail
Pretreatment with parenteral anticoagulation in patients with ST-segment elevation myocardial infarction: a systematic review and meta-analysis
Doctor F. Albuquerque (Carnaxide, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Risk stratification and management of acute coronary syndromes

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023
You may be interested in
thumbnail
Congress Presentation
A novel strategy for reducing time between antiplatelet drug cessation and urgent CABG surgery following acute coronary syndromes
thumbnail
Congress Presentation
Anticoagulant monotherapy versus anticoagulant therapy in combination with single antiplatelet agent in patients after coronary artery bypass grafting - analysis of real-world data
thumbnail
Congress Presentation
Influence of baseline Hb1Ac and antiplatelet therapy on 5-year clinical outcomes after coronary artery bypass grafting.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources